What the headline success figures actually mean

Across published cohort studies and specialist outcome summaries, between 70% and 85% of patients treated with ChondroFiller report 'good to excellent' results — meaning meaningful pain reduction, improved joint function, and sustained mobility gains, typically assessed at one to five years after the procedure.

Those figures come from standardised questionnaires that ask patients how much pain and limitation they experience day to day, alongside MRI-based assessments of how well the defect has filled. The knee scores used include the IKDC and Lysholm scales; hip outcomes use the Harris Hip Score; and defect fill on MRI is graded using MOCART scoring, where published cohorts return values of 70–87 out of 100 — indicating clinically meaningful repair without implying full restoration of native cartilage. ChondroFiller works by providing an acellular scaffold that recruits the body's own cells into the defect — a process called matrix-induced chondrogenesis — rather than directly regrowing cartilage.

The evidence behind these numbers is real but modest. Published data come mainly from small, non-randomised European cohorts, so the 70–85% figure is a directional guide rather than a guaranteed personal probability. The fact that over 19,000 cases have been performed globally does add procedural confidence, even where large randomised trial data remain limited.

The studies behind the numbers

Four datasets form the core of the published evidence, each adding a different piece to the picture.

The strongest single cohort is Mazek (2021), a prospective study of 26 hip patients followed for 12 to 60 months. At three to five years, 17 of 21 evaluable patients (81%) maintained good or excellent results, with statistically significant functional improvement from baseline. Patients with advanced osteoarthritis (Tönnis grade 2–3) fared poorly — a consistent finding across the wider literature that reinforces how heavily outcomes depend on patient selection.

A 2024 Bulgarian knee study (n=17, mean age 31) tracked Lysholm and IKDC scores at three, six, and 12 months, recording significant improvements at every time point. Gains appeared to plateau between six and twelve months — no statistically significant difference between the two — suggesting functional recovery largely stabilises within the first year rather than continuing to accumulate.

A 2025 study extended the indication to the wrist, comparing 25 treated patients against seven controls. Cartilage quality was significantly better in the ChondroFiller group (median Outerbridge score 1.5 versus 3; p=0.006), broadening the potential application beyond larger joints.

The only randomised trial, published in 2016 (n=23), showed significant IKDC improvement in the ChondroFiller arm at every follow-up point, with good MRI evidence of defect integration. A dropout rate of roughly 60% in the microfracture comparison arm means the trial cannot support any claim of superiority over microfracture — or any other established technique. No adequately powered RCT against ACI or mosaicplasty currently exists, and follow-up across all published work rarely exceeds five years.

Outcome scores in plain language

Clinical outcome scores can feel abstract until they map onto everyday activity. The IKDC (International Knee Documentation Committee) scale runs from 0 to 100, with 100 representing no limitation at all. A patient entering treatment with a symptomatic focal cartilage defect typically scores in the 40–50 range — a level where stair-climbing and sustained walking are genuinely difficult. A gain of roughly 30 points moves that patient toward the 70–80 band, which broadly corresponds to returning to low-impact activity and experiencing noticeably reduced pain at rest.

For hip patients, the Harris Hip Score (also 0–100) works similarly: an improvement of approximately 33 points from a moderate baseline typically means greater walking tolerance, easier stair use, and less pain disturbing sleep. The Lysholm knee scale — which specifically captures swelling, instability, and locking — showed statistically significant gains at every three-monthly checkpoint in the 2024 Bulgarian cohort, confirming these are not just numerically positive trends.

On MRI, good integration of the scaffold with surrounding tissue does not confirm that the repair matches the mechanical quality of native hyaline cartilage — the tissue formed is fibrocartilage, as noted earlier. What MRI confirmation does indicate is that the defect space has filled and the material has bonded with adjacent tissue, which is the expected prerequisite for functional recovery.

Functional gains appear to level off between six and twelve months. That plateau is not a sign of deterioration; it reflects normal tissue maturation reaching a stable endpoint, and patients should plan rehabilitation goals accordingly rather than expecting further incremental improvement beyond that window.

How ChondroFiller works and what tissue it produces

The scaffold itself contains no cells. ChondroFiller is a type I collagen hydrogel — a temporary matrix manufactured by Meidrix Biomedicals (Germany) and CE-marked as a Class III medical device — that sets within minutes of being placed into a focal cartilage defect. It then acts as a structural framework for the patient's own progenitor cells to migrate in from surrounding synovium and subchondral bone, a process called acellular matrix-induced chondrogenesis.

That cell migration is measurable. A 2025 ex vivo osteochondral model recorded a 2.4-fold increase in DNA content within the scaffold by day 14, confirming that infiltration occurs and progresses meaningfully within the first fortnight. Augmenting the scaffold with mesenchymal stem cells further boosted collagen and glycosaminoglycan production in the same model, though current clinical use relies on the patient's own endogenous cell supply.

The cells that colonise the scaffold tend to produce fibrocartilage rather than the hyaline cartilage that originally lined the joint surface. Fibrocartilage is mechanically inferior under sustained load — a genuine limitation: the defect fills and integrates, but the replacement tissue does not replicate the durability of native cartilage.

Early loading carries a separate practical risk. A 2024 biomechanical in-vitro study found that ChondroFiller's initial mechanical instability does not protect the opposing cartilage surface from damage before stable defect filling is established. Avoiding full weight-bearing in the early post-treatment period is therefore a clinical priority rather than an optional precaution.

ChondroFiller is CE-marked for use in Europe and is not FDA-approved; the product is currently unavailable in the United States.

Which patients tend to respond best

Candidacy for ChondroFiller turns primarily on the nature of the cartilage defect rather than symptom severity alone. The patients who tend to do best have a focal, full-thickness lesion in an otherwise healthy joint, typically aged under 50, with surrounding cartilage largely intact. That surrounding tissue matters because the scaffold relies on the patient's own progenitor cells migrating in from nearby structures; widespread cartilage loss removes much of that cell supply.

For hip applications, joint health is stratified by Tönnis grade. Published cohorts — including Mazek (2021) — consistently show good or excellent outcomes in Tönnis grade 0 or 1 joints, while those with grade 2 or 3 (moderate to advanced osteoarthritis) fare poorly. Advanced OA is a consistent contraindication across the literature, not a borderline consideration.

Equivalent criteria apply in the knee and ankle: diffuse or widespread cartilage loss is not an appropriate indication, and imaging will typically confirm focal disease before the pathway is recommended.

Defect size is also relevant. A 2 cm² threshold appears frequently in the evidence, but whether outcomes differ conclusively above or below that boundary has not yet been established — it remains one of several factors weighed during specialist assessment rather than a fixed cut-off.

ChondroFiller is available across the knee, hip, ankle, and small joints: a 2025 wrist study confirmed significantly better cartilage quality scores versus untreated controls (Outerbridge 1.5 vs 3; p=0.006), extending the indication beyond the major weight-bearing joints.

Individual suitability depends on the full clinical picture, including imaging, functional status, and activity goals — factors a specialist will assess at consultation.

Finding a suitable specialist

Deciding whether ChondroFiller is appropriate for a particular joint requires a formal assessment — symptoms alone are not enough to establish candidacy. A specialist with cartilage-treatment experience will review imaging, map the defect, consider surrounding joint health, and weigh previous treatments before recommending a pathway. Relevant clinicians include orthopaedic surgeons and sports-medicine consultants who list cartilage preservation among their areas of practice.

Questions worth raising at an initial consultation:

• How large is the defect, and does it fall within the published evidence base for this procedure?
• What is the OA grade of the surrounding joint, and how does that affect the likely prognosis?
• What weight-bearing restrictions will apply, and for how long?
• When would functional gains be expected to plateau, and what does longer-term follow-up involve?

Most published data suggest the majority of functional improvement occurs within the first six to twelve months. Follow-up in the literature rarely extends beyond five years, and the only randomised comparison with a rival technique lost most of its control arm — leaving questions of long-term durability and comparative superiority open. For a younger patient weighing a joint-preservation option against what the joint may look like a decade on, those gaps are worth pressing at assessment rather than leaving unasked.

Find a specialist

Search MSK lists orthopaedic surgeons and sports-medicine clinicians across the UK who offer ChondroFiller and related cartilage injection treatments — filter by region and specialty to find one near you.